Annual Report 2003 Aventis - Sanofi

More documents

Recommendations

Info

ADDENDUM April 30, 2004 Recent Developments Aventis Supervisory Board recommends substantially improved offer from Sanofi-Synthélabo in order to create Sanofi-Aventis On April 25, 2004, Sanofi-Synthélabo submitted to the Aventis Management Board a substantially improved offer to acquire Aventis. After reviewing this new offer, which creates considerably more value for shareholders and provides for a balanced corporate governance structure, both the Management Board and the Supervisory Board of Aventis decided to recommend it to Aventis shareholders. Aventis shareholders will be informed of all terms of the offer and the principles for the new combined company in the coming weeks. Aventis · 67917 Strasbourg · Cedex 9 · France · www.aventis.com · Telephone +33 (0) 388 99 1100 · Fax +33 (0) 388 99 1101 · info@aventis.com · Address for visitors: 16, Avenue de l‘Europe · Espace Européen de l‘Entreprise · F-67300 Schiltigheim Aventis, a stock corporation with a Supervisory Board and Management Board, and a share capital of e 3,064,758,522.74 - 542 064 308 RCS Strasbourg
Financial Highlights Net Sales (in e million) Activity Variance (1) EBITA (2) Margin (in % of sales) Net Income (in e million) Research and Development (in e million) Capital Expenditures (in e million) 2003 16 791 27.4 2 444 2 863 773 2002 17 591 25.6 2 081 3 141 864 Total Variance (1) Excluding currency translation effects (2) Unaudited non-GAAP measure we define as operating income before goodwill amortization plus equity in earnings of affiliated companies The above figures refer to the Aventis core business (prescription drugs, human vaccines, our 50 % equity stake in the Merial animal health joint venture, and corporate activities). This report is being provided for information purposes only. Aventis prepares a legally binding annual report in French known as the “Document de Référence” prior to its Annual General Meeting as well as an annual report in English on Form 20-F pursuant to the U.S. Securities Exchange Act of 1934. -4.5 % 5.9 % +1.8 p.p. 17.5 % -9 % -11 % Key Aventis Share Data Basic Earnings per Share (in e) Basic Earnings per Share before Goodwill Amortization (in e) Number of shares as of December 31 Per share information (in e) Dividend Price-earnings ratio Stockholders’ equity (in e billion) Year-end share price High Low Market capitalization as of December 31 (in e billion) Average daily trading volume (number of shares) Paris New York Frankfurt 2003 3.11 3.72 802 292 807 0.82 16.85 10.4 52.40 54.55 37.50 42.04 3 512 837 304 342 52 640 2002 2.62 3.31 799 474 490 0.70 19.77 11.3 51.80 85.95 47.60 41.41 2 920 038 260 116 64 766
Page 1: Life can’t wait. Aventis 2003 Ann
Page 5 and 6: Therapeutic Area Key Developments R
Page 7 and 8: Letter to Shareholders Dear Shareho
Page 9 and 10: Meeting Future Challenges >> 4
Page 11 and 12: Report of the Supervisory Board Dea
Page 13 and 14: 8
Page 16 and 17: 11
Page 18 and 19: Aventis Strategic Brands Taxotere (
Page 20: Expert Opinion on Oncology >> 15
Page 23 and 24: Medical Background Diabetes mellitu
Page 25 and 26: Production and Manufacturing Meetin
Page 28 and 29: 23
Page 30 and 31: Aventis Human Vaccines Pediatric co
Page 32: Expert Opinion on Immunization >> 2
Page 35 and 36: Medical Background Deep vein thromb
Page 37 and 38: Sales and Marketing The Power of Ev
Page 40 and 41: 35
Page 42 and 43: Aventis Strategic Brands Allegra /
Page 44 and 45: Expert Opinion on Infectious Diseas
Page 46 and 47: Targocid (teicoplanin) is a consist
Page 48 and 49: Key Regulatory Achievements in 2003
Page 50 and 51: program is designed to enable Avent
Page 52 and 53:
Africa, we supplied 60 000 vials of
Page 54 and 55:
Nutrition and Aventis CropScience i
Page 56 and 57:
51
Page 58 and 59:
still constitute a signifi cant par
Page 60 and 61:
Your Contacts Your Contacts at Aven
Page 62 and 63:
Brand names appearing in italics th
show all

Annual Report 2003 Aventis - Sanofi

Create successful ePaper yourself

Delete template?

Save as template?